NO20074867L - Antistoffer mot CCR5 og anvendelser derav - Google Patents

Antistoffer mot CCR5 og anvendelser derav

Info

Publication number
NO20074867L
NO20074867L NO20074867A NO20074867A NO20074867L NO 20074867 L NO20074867 L NO 20074867L NO 20074867 A NO20074867 A NO 20074867A NO 20074867 A NO20074867 A NO 20074867A NO 20074867 L NO20074867 L NO 20074867L
Authority
NO
Norway
Prior art keywords
seq
group
cdr2
cdr3
antibody
Prior art date
Application number
NO20074867A
Other languages
English (en)
Inventor
Ralf Schumacher
Michael Brandt
Stefan Seeber
Suryanarayana Sankuratri
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of NO20074867L publication Critical patent/NO20074867L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

SAMMENDRAG Et antistoff som binder til human CCR5 omfattende en variabel tung kjede og en variabel lett kjede, karakterisert ved at den variable tunge kjeden omfatter CDR-sekvensene CDR1, CDR2 og CDR3 og CDR1 er valgt fra gruppen bestående av SEKV ID NR: 9, 10, 11, 12, CDR2 er valgt fra gruppen bestående av SEKV ID NR: 13, 14, 15, CDR3 er valgt fra gruppen bestående av SEKV ID NR: 16, 17, hvor nevnte CDR'er er valgt uavhengig av hverandre eller er en kimær, humanisert variant eller et fragment av nevnte antistoff, har fordelaktige egenskaper for behandling av immunosuppressive sykdommer.
NO20074867A 2005-04-01 2007-09-25 Antistoffer mot CCR5 og anvendelser derav NO20074867L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05007138 2005-04-01
PCT/EP2006/002974 WO2006103100A2 (en) 2005-04-01 2006-03-31 Antibodies against ccr5 and uses thereof

Publications (1)

Publication Number Publication Date
NO20074867L true NO20074867L (no) 2007-12-07

Family

ID=34934663

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20074867A NO20074867L (no) 2005-04-01 2007-09-25 Antistoffer mot CCR5 og anvendelser derav

Country Status (19)

Country Link
US (1) US7615216B2 (no)
EP (2) EP2336183A3 (no)
JP (2) JP4733736B2 (no)
KR (1) KR20070116136A (no)
CN (1) CN101175771A (no)
AR (1) AR052959A1 (no)
AU (1) AU2006228663A1 (no)
BR (1) BRPI0609792A2 (no)
CA (1) CA2603692A1 (no)
CR (1) CR9393A (no)
IL (1) IL186071A0 (no)
MA (1) MA29374B1 (no)
MX (1) MX2007011842A (no)
NO (1) NO20074867L (no)
RU (1) RU2007139953A (no)
SG (1) SG151284A1 (no)
TW (1) TW200720289A (no)
WO (1) WO2006103100A2 (no)
ZA (1) ZA200708332B (no)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009525301A (ja) * 2006-01-30 2009-07-09 エフ．ホフマン−ラ ロシュ アーゲー Ｈｉｖを処置するための相乗的組成物
TW200817438A (en) 2006-08-17 2008-04-16 Hoffmann La Roche A conjugate of an antibody against CCR5 and an antifusogenic peptide
CN101516914A (zh) 2006-09-29 2009-08-26 霍夫曼-拉罗奇有限公司 针对ccr5的抗体及其应用
US20090143288A1 (en) 2007-03-13 2009-06-04 Roche Palo Alto Llc Peptide-complement conjugates
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
KR20100097737A (ko) * 2008-01-15 2010-09-03 에프. 호프만-라 로슈 아게 Ｃｃｒ５에 대한 어푸코실화된 항체 및 이의 용도
WO2010028796A1 (en) * 2008-09-10 2010-03-18 F. Hoffmann-La Roche Ag Trispecific hexavalent antibodies
WO2010028798A1 (en) * 2008-09-10 2010-03-18 F. Hoffmann-La Roche Ag Multivalent antibodies
JP2012513425A (ja) 2008-12-22 2012-06-14 エフ．ホフマン−ラ ロシュ アーゲー 免疫グロブリンの精製
CA2756244A1 (en) 2009-04-02 2010-10-07 Roche Glycart Ag Multispecific antibodies comprising full length antibodies and single chain fab fragments
SG175077A1 (en) 2009-04-07 2011-11-28 Roche Glycart Ag Trivalent, bispecific antibodies
PE20120540A1 (es) 2009-05-27 2012-05-09 Hoffmann La Roche Anticuerpos triespecificos o tetraespecificos
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
TW201113037A (en) 2009-08-28 2011-04-16 Hoffmann La Roche Antibodies against CDCP1 for the treatment of cancer
TWI412375B (zh) 2009-08-28 2013-10-21 Roche Glycart Ag 人類化抗ｃｄｃｐ１抗體
EP2475991A1 (en) 2009-09-07 2012-07-18 F. Hoffmann-La Roche AG Es-ms of glycopeptides for analysis of glycosylation
EP2478013B1 (en) 2009-09-16 2018-10-24 F.Hoffmann-La Roche Ag Coiled coil and/or tether containing protein complexes and uses thereof
RS54795B1 (sr) 2009-12-22 2016-10-31 Roche Glycart Ag Anti-her3 antitela i njihova korišćenja
TW201138821A (en) 2010-03-26 2011-11-16 Roche Glycart Ag Bispecific antibodies
WO2012010582A1 (en) 2010-07-21 2012-01-26 Roche Glycart Ag Anti-cxcr5 antibodies and methods of use
CN103068846B9 (zh) 2010-08-24 2016-09-28 弗·哈夫曼-拉罗切有限公司 包含二硫键稳定性Fv片段的双特异性抗体
AU2011311673B2 (en) 2010-10-05 2015-09-17 F. Hoffmann-La Roche Ag Antibodies against human TWEAK and uses thereof
SG191153A1 (en) 2010-12-23 2013-07-31 Hoffmann La Roche Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
EP2678358B1 (en) * 2011-02-23 2015-07-22 F.Hoffmann-La Roche Ag Antibodies against human il33r and uses thereof
AR085404A1 (es) 2011-02-28 2013-09-25 Hoffmann La Roche Proteinas de union a antigeno
MX342034B (es) 2011-02-28 2016-09-12 Hoffmann La Roche Proteinas monovalentes que se unen a antigenos.
WO2013024022A1 (en) 2011-08-12 2013-02-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treatment of pulmonary hypertension
JP6041882B2 (ja) 2011-09-23 2016-12-14 ロシュ グリクアート アーゲー 二重特異性抗ｅｇｆｒ／抗ｉｇｆ−１ｒ抗体
SG2014012470A (en) 2011-10-05 2014-06-27 Hoffmann La Roche Process for antibody g1 glycoform production
CA2861124A1 (en) 2012-02-10 2013-08-15 Genentech, Inc. Single-chain antibodies and other heteromultimers
MX2014014162A (es) 2012-05-24 2015-02-04 Hoffmann La Roche Anticuerpos multiespecificos.
KR20150030744A (ko) 2012-06-27 2015-03-20 에프. 호프만-라 로슈 아게 표적에 특이적으로 결합하는 하나 이상의 결합 단위를 포함하는 항체 Ｆｃ－영역 접합체의 제조 방법 및 그의 용도
RU2639287C2 (ru) 2012-06-27 2017-12-20 Ф. Хоффманн-Ля Рош Аг Способ отбора и получения высокоселективных и мультиспецифичных нацеливающих групп с заданными свойствами, включающих по меньшей мере две различные связывающие группировки, и их применения
AR094403A1 (es) 2013-01-11 2015-07-29 Hoffmann La Roche Terapia de combinación de anticuerpos anti-her3
BR112016006929A2 (pt) 2013-10-11 2017-09-19 Hoffmann La Roche Anticorpo, ácido nucleico, vetor de expressão, célula hospedeira, métodos de preparação de anticorpo, de tratamento de pacientes e de geração de um anticorpo, composição farmacêutica e uso do anticorpo
WO2015082446A1 (en) 2013-12-02 2015-06-11 F. Hoffmann-La Roche Ag Treatment of cancer using an anti-cdcp1 antibody and a taxane
UA117289C2 (uk) 2014-04-02 2018-07-10 Ф. Хоффманн-Ля Рош Аг Мультиспецифічне антитіло
EP3227332B1 (en) 2014-12-03 2019-11-06 F.Hoffmann-La Roche Ag Multispecific antibodies
WO2018106945A1 (en) 2016-12-07 2018-06-14 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
EP3554541B1 (en) 2016-12-14 2023-06-07 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor
AU2019302603A1 (en) 2018-07-13 2021-01-14 Nanjing Legend Biotech Co., Ltd. Co-receptor systems for treating infectious diseases
EP3883635A1 (en) 2018-11-19 2021-09-29 Progenity, Inc. Methods and devices for treating a disease with biotherapeutics
JP7638989B2 (ja) 2019-11-21 2025-03-04 ユニティ バイオテクノロジー インコーポレイテッド Ｔｉｅ－２に対する抗体および使用方法
CN115666704B (zh) 2019-12-13 2025-09-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置
US11629196B2 (en) 2020-04-27 2023-04-18 Incelldx, Inc. Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
WO1987005330A1 (en) 1986-03-07 1987-09-11 Michel Louis Eugene Bergh Method for enhancing glycoprotein stability
US4791192A (en) * 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5202238A (en) * 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US6743594B1 (en) * 1995-06-06 2004-06-01 Human Genome Sciences, Inc. Methods of screening using human G-protein chemokine receptor HDGNR10 (CCR5)
WO1997045543A2 (en) * 1996-05-28 1997-12-04 The Government Of The United States Of America, As Represented By The Secretary Of Health And Human Services, National Institutes Of Health Cc chemokine receptor 5, antibodies thereto, transgenic animals
US6528625B1 (en) * 1996-10-28 2003-03-04 Millennium Pharmaceuticals, Inc. Anti-CCR5 antibodies and kits comprising same
EP0983303B1 (en) 1997-05-21 2006-03-08 Biovation Limited Method for the production of non-immunogenic proteins
US6610834B1 (en) 1998-11-18 2003-08-26 Peter I. Lobo Human IgM antibodies to chemokine receptors
US20030099645A1 (en) * 2000-10-10 2003-05-29 Lobo Peter Isaac Naturally occuring IgM antibodies that bind to membrane receptors on lymphocytes
AU776910B2 (en) 1998-12-08 2004-09-23 Merck Patent Gesellschaft Mit Beschrankter Haftung Modifying protein immunogenicity
CA2355607A1 (en) 1998-12-16 2000-06-22 Progenics Pharmaceuticals, Inc. Anti-ccr5 antibody
ES2233359T3 (es) 1999-03-11 2005-06-16 Micromet Ag Construcciones de anticuerpos dirigidos contra el ccr5 y su empleo en el tratamiento de enfermedades autoinmunologicas.
AU2841101A (en) * 1999-12-08 2001-06-18 Novartis Ag Methods and compositions useful for inhibiting ccr5-dependent infection of cellsby hiv-1
AU2265701A (en) 1999-12-16 2001-06-25 Tanox, Inc. Anti-hiv-1 conjugates for treatment of hiv disease
EP1263791A4 (en) * 2000-02-09 2004-07-07 Human Genome Sciences Inc HUMAN G-PROTEIN CHEMOKIN RECEPTOR HDGNR10 (CCR5 RECEPTOR)
US20040043033A1 (en) 2000-05-01 2004-03-04 Green Lorrence H. Method and vaccine for the prevention of AIDS
US7138119B2 (en) 2000-09-15 2006-11-21 Progenics Pharmaceuticals, Inc. Compositions and methods for inhibition of HIV-1 infection
US7005503B2 (en) 2002-02-08 2006-02-28 Genetastix Corporation Human monoclonal antibody against coreceptors for human immunodeficiency virus
US20030165988A1 (en) * 2002-02-08 2003-09-04 Shaobing Hua High throughput generation of human monoclonal antibody against peptide fragments derived from membrane proteins
US20020147147A1 (en) * 2000-11-16 2002-10-10 Karin Molling Nucleic acid molecules encoding a protein interacting with the chemokine receptor CCR5 or other chemokine receptor family members
EP1207202A1 (en) 2000-11-16 2002-05-22 Mölling, Karin, Inst. für med. Virologie der Uni. Zürich Nucleic acid molecules encoding a protein interacting with the chemokine receptor CCR5 or other chemokine receptor family members
US7175988B2 (en) 2001-02-09 2007-02-13 Human Genome Sciences, Inc. Human G-protein Chemokine Receptor (CCR5) HDGNR10
US20030003440A1 (en) * 2001-03-14 2003-01-02 Lucia Lopalco Novel CCR5 epitope and antibodies against it
US7060273B2 (en) * 2001-04-06 2006-06-13 Progenics Pharmaceuticals, Inc. Methods for inhibiting HIV-1 infection
US20020146415A1 (en) 2001-04-06 2002-10-10 Olson William C. Methods for inhibiting HIV-1 infection
DE60237704D1 (de) 2001-10-16 2010-10-28 Government Of The Us Secretary Neutralisierende antikörper gegen hiv mit breiter kreuzreaktion, die mit hilfe von env-cd4-co-rezeptorkomplexen selektiert werden
WO2003066830A2 (en) 2002-02-08 2003-08-14 Genetastix Corporation Human monoclonal antibodies against membrane proteins
NZ534947A (en) 2002-02-22 2008-03-28 Progenics Pharm Inc Anti-CCR5 antibody that binds to CCR5 on the surface of a human cell.
US7122185B2 (en) * 2002-02-22 2006-10-17 Progenics Pharmaceuticals, Inc. Anti-CCR5 antibody

Also Published As

Publication number Publication date
MA29374B1 (fr) 2008-04-01
CR9393A (es) 2008-02-20
TW200720289A (en) 2007-06-01
SG151284A1 (en) 2009-04-30
WO2006103100A3 (en) 2006-12-28
WO2006103100A2 (en) 2006-10-05
US20070036796A1 (en) 2007-02-15
KR20070116136A (ko) 2007-12-06
BRPI0609792A2 (pt) 2010-04-27
AU2006228663A1 (en) 2006-10-05
MX2007011842A (es) 2007-10-11
US7615216B2 (en) 2009-11-10
JP4733736B2 (ja) 2011-07-27
AR052959A1 (es) 2007-04-11
JP2008533998A (ja) 2008-08-28
EP2336183A3 (en) 2011-10-12
EP2336183A2 (en) 2011-06-22
RU2007139953A (ru) 2009-05-10
JP2011079836A (ja) 2011-04-21
CN101175771A (zh) 2008-05-07
IL186071A0 (en) 2008-01-20
ZA200708332B (en) 2009-04-29
CA2603692A1 (en) 2006-10-05
EP1869087A2 (en) 2007-12-26

Similar Documents

Publication Publication Date Title
NO20074867L (no) Antistoffer mot CCR5 og anvendelser derav
NZ623319A (en) Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
NZ604090A (en) Human anti-b7rp1 neutralizing antibodies
NO20066052L (no) Anti-CD3 antistoffer og fremgangsmater for anvendelse derav
NL300911I2 (nl) sarilumab
PE20120079A1 (es) Moleculas de anticuerpos mejoradas
NZ712765A (en) Antibodies that bind csf1r
NZ596042A (en) Humanized anti-factor d antibodies
NZ601342A (en) Antibodies that bind il-4 and/or il-13 and their uses
NZ605980A (en) Anti-fap antibodies and methods of use
NZ595464A (en) Alpha-4-beta-7 heterodimer specific antagonist antibody
EP2471817A3 (en) Humanized antibody molecules specific for IL-31
PE20141398A1 (es) Anticuerpos neutralizantes de citomegalovirus humano
NZ601617A (en) Folate receptor 1 antibodies and immunoconjugates and uses thereof
NZ610734A (en) Human antibodies to the glucagon receptor
NZ599683A (en) Anti-ilt7 antibody
NZ628528A (en) Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
ES2572231T3 (es) Anticuerpos monoclonales anti-IL-21 humana
MX2011008843A (es) Anticuerpos humanizados que se unen a cd19 y sus usos.
NZ599497A (en) Humanized antibodies to amyloid beta
ES2570153T3 (es) Anticuerpos anti-C5aR con propiedades mejoradas
NZ596712A (en) Anti cxcr4 antibodies for the treatment of hiv
MX341958B (es) Anticuerpos contra el il33r humano y usos de los mismos.
EA032189B9 (ru) Изолированные человеческие моноклональные антитела против ингибитора пути тканевого фактора (tfpi) и фармацевтическая композиция, содержащая их
NZ598670A (en) Antibodies against glucagon receptor and their use

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application